Breaking Finance News

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has been upgraded to Hold in a statement by BidaskClub earlier today.

Having a price of $6.40, Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) traded 6.41% higher on the day. With the last close down -12.18% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the same time period. The company has recorded a 50-day moving average of $6.27 and a 200-day moving average of $7.09. 539,053 shares of the stock traded hands, down from an average trading volume of 567,677

BidaskClub has upgraded Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) to Hold in a statement released on 7/8/2017.

On Thursday March 30, 2017, Cantor Fitzgerald released a statement about Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) upped the target price from $17.00 to $24.00 that suggested an upside of 1.67%.

See Chart Below

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings Inc has a 52 week low of $2.95 and a 52 week high of $10.78 The company’s market cap is currently $0.

In addition to BidaskClub reporting its stock price target, a total of 1 broker has issued a research note on the company. The average stock price target is $6.00 with 0 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *